Bluepha
蓝晶微生物
Bluepha (蓝晶微生物) is a Chinese synthetic-biology company founded in October 2016 by Tsinghua professor Chen Guoqiang and PhDs Li Teng and Zhang Haoqian, with Zhang serving as co-founder and CEO . The company designs, develops and manufactures novel bio-based molecules and materials, positioning itself as a molecular-and-materials innovator powered by synthetic biotechnology . Its flagship product is PHA (polyhydroxyalkanoates), a fully biodegradable bioplastic for which Bluepha has claimed to be the world's only full-range provider ; by early 2022 it had begun construction on a 25,000-ton-per-year "super-factory" in Yancheng, Jiangsu, and had secured orders and意向 orders from multiple Fortune 500 clients . FreeS Fund (峰瑞资本) led Bluepha's angel round in early 2017 and has followed on through at least six consecutive rounds, citing conviction in the intersection of computation and biology for greener, higher-performance materials .
AI-generated — may contain errors, please verify.
Coverage
Congratulations to METiS Pharmaceuticals on its Hong Kong Stock Exchange IPO — FreeS Fund invested in four consecutive early rounds.
From Whiteboard Equations to the "SpaceX" of Pharma
峰瑞资本·Spend a Summer on a VC Journey of "Seeking Truth" and "Taking Things Seriously" | FreeS Fund's 2024 Internship Program Is Now Open
Welcome aboard — a great workplace is one with a bunch of amazing colleagues.
峰瑞资本·"Yinghua Chenrui" Zhou Zhen: Solving Biomaterial Industry Bottlenecks with Unique Modification Technology and Processing Techniques | Linear Capital Portfolio Interview Series
In late December 2023, bio-based materials high-performance modification and application innovation company **Yinghua Chenrui** announced the completion of a tens of millions of RMB angel funding round.
线性资本·Bio-materials high-performance modification and application innovation company "Yinghua Chenrui" raises tens of millions of RMB in angel funding, led by Linear Capital
Output high-performance bio-based material modification capabilities.
线性资本·The 6 Questions Young People Care About Most: We Asked 17 Founders | FreeS Fund Youth Festival & Graduation Season Special
Passion and conviction are what carry you through the darkness.
峰瑞资本·Setting Off in Spring: 7 Early-Stage Companies Raise Over 800 Million | FreeS Family Funding News · Vol 14
Looking forward to working with more outstanding founders.
峰瑞资本·Fan Bao's disappearance is a situation no one wanted to see.
"The Long March has only just begun."
暗涌Waves·How to Invest in Biotech in 2023? | FreeS Research
Data-driven, cross-disciplinary, bearing fruit — the most certain direction amid uncertainty
峰瑞资本·The Past and Future of ESG: From Dividing the Pie to Growing It | FreeS Research
A Complete Guide to ESG ESG — Environmental, Social, and Governance — has evolved from a niche investment framework into a mainstream lens for evaluating companies. Yet for many in China's tech and investment circles, it remains more buzzword than business practice. Here's what actually matters. **The Three Pillars** *Environmental* covers a company's carbon footprint, resource use, waste management, and broader ecological impact. For Chinese manufacturers, this increasingly means compliance with the EU's Carbon Border Adjustment Mechanism (CBAM) and domestic dual-carbon targets — not just greenwashing. *Social* encompasses labor practices, supply chain ethics, data privacy, and community relations. In China's context, this gets complicated fast: tech platforms face scrutiny over algorithmic labor management (think Meituan's delivery riders), while consumer brands navigate Xinjiang cotton controversies that can tank overseas sales overnight. *Governance* examines board structure, executive compensation, shareholder rights, and anti-corruption measures. For Chinese companies listing in the U.S. or Hong Kong, this includes VIE structure transparency
峰瑞资本·The U.S.-China Biotech Race: Where Are the Opportunities in Synthetic Biology? | FreeS Fund Dialogue
Over the next five to ten years, which technologies will have a significant impact on synthetic biology?
峰瑞资本·FreeS Fund's Seventh Anniversary: Working Together to Go Further
Welcome to the team.
峰瑞资本·[Live Tomorrow] In Conversation with Bluepha | Synthetic Biology: From Groping in the Dark to Riding the Wave
Going live tomorrow at 10 a.m. sharp.
峰瑞资本·Untangling the Ins and Outs of Carbon Emissions to Find the Path to Carbon Neutrality | FreeS Research Institute
What Investment Opportunities Exist in the Hundred-Trillion-Yuan Carbon Neutrality Market?
峰瑞资本·How Should We Think About Green Investing? | FreeS Research Institute
Why Does Carbon Neutrality Have to Be Zero?
峰瑞资本·What Are the Opportunities for Biotech Over the Next Decade? | A FreeS Fund Conversation
Breaking Through the "Great Stagnation" in Technology: Biotechnology Is a Critical Breakthrough
峰瑞资本·Why Are Chinese and American VCs Drifting Apart? | Li Feng Column
"Shifting from Virtual to Even More Virtual" vs. "Shifting from Virtual to Real"
峰瑞资本·What Happens When the Hottest Tech Sectors Collide? | FreeS Fund Chip Series
How do cross-disciplinary ventures that push the boundaries of imagination achieve steady, grounded commercialization?
峰瑞资本·Interdisciplinary Frontier Entrepreneurship: How Chips Are Reshaping Every Industry | May 15 Livestream Registration
See you on May 15!
峰瑞资本·4 Companies Raise Nearly 2 Billion RMB in Total | FreeS Family Funding News · Vol 8
Walk alongside more outstanding founders.
峰瑞资本·Farewell to a Year of Inflection Points: Will 2022 Be Better? | Li Feng's New Year Outlook
Where the heart leads, steady steps take you far.
峰瑞资本·Our Year: Working Together, Staying the Course | FreeS Fund 2021 Year in Review
Walk alongside more outstanding founders.
峰瑞资本·Synthetic Biology: The *Heavenly Crafts* of the Next Twenty Years | 2021 FreeS Fund Annual Investor Summit
How will the convergence of biotechnology and data science transform the production methods for over 60% of the world's physical goods?
峰瑞资本·FreeS Fund Report 25: Food Investment Through the Lens of China's Dietary Structure
What will we eat in the future?
峰瑞资本·New Opportunities Amid the Great Transformation in Drug R&D | FreeS Fund Dialogue Session 2 Now Open for Registration
Breakthroughs and Acceleration in New Drug R&D
峰瑞资本·The Rise and Fall of Education, Consumer Bubbles, Carbon Neutrality, Commercial Spaceflight... "Cool" Reflections on Hot Investment Topics | Li Feng Column
Exploring Opportunities Amid "Major Restructuring"
峰瑞资本·Biotech Firms Raise Nearly 4 Billion Yuan, Consumer Companies Land Over 1.4 Billion | FreeS Family Funding Roundup · August
We've also released three short videos this week — follow us to check them out.
峰瑞资本·FreeS Report 22: Can New Materials Save the Footwear and Apparel Industry? | FreeS Research Institute
Are New Materials Really Just a Gimmick?
峰瑞资本·Early-Stage Medical Aesthetics Investment Shifts Toward Underlying Technology | FreeS Research
Self-Pampering Psychology or Appearance Anxiety? Exploring the Underlying Drivers of the Trillion-Yuan Medical Aesthetics Industry
峰瑞资本·FreeS Fund 2021 Outlook ② | Three Trends in Biomedical Innovation
The Biopharma Industry Enters the "Three Fast" Era
峰瑞资本·How to Break Through Innovation with the Power of Interdisciplinary Collaboration? | FreeS Fund Biomedical and Pharmaceutical Investment Summit Transcript
What should you do if you discover a mismatch between technology and market?
峰瑞资本·Blue Ocean Strategy: How Early-Stage Biopharma Startups Can Break Through and Win with Big Pharma | FreeS Fund 2020 Biopharma Summit Session 3 — Registration Open
From "Me Worse" to "First in Class": How Can Biopharma Companies Compete Through Differentiation?
峰瑞资本·Li Feng: One Chart to Decode Biotech Innovation Opportunities | Your Complete Guide to the FreeS Fund 2020 Biomedical Summit
Three Livestreams and One Offline Symposium, Decoding the Era of Biomedical Innovation
峰瑞资本·FreeS Fund Healthcare Open Day Is Here: Entering the Grand Era of Biomedical Innovation
Looking for China's Genentech, Moderna, Alnylam, Spark, Nimbus Therapeutics
峰瑞资本·FreeS Fund received eight recognitions from institutions including *Fortune* (Chinese edition), 36Kr, and the Fund of Funds Alliance.
Do what's right, not what's easy.
峰瑞资本·Our Past 100 Days: Sailing Against the Wind, Growing Toward the Sun
Venture Capital's Pandemic Fight: A Chronicle
峰瑞资本·5 Deals, Double 11 Results Roundup, 24+ Awards... 42 Highlights and 7 Insights | FreeS Fund Blackboard · November
Do what's right, not what's easy
峰瑞资本·Bluepha Closes RMB 40 Million Series A Round | FreeS Fund Deal Brief
Leading Global Engineered Microbe Development
峰瑞资本·Acquisitions, New Brand Entrepreneurship Courses, and More: 21 Developments and 4 Reflections | FreeS Fund Chalkboard · October
Do what's right, not what's easy.
峰瑞资本·Beauty Brands Entering China, Becoming India's Third-Largest E-Commerce Player, and Betting on Biomedical — 22 Developments and 5 Takeaways | FreeS Fund Bulletin · September
Do what's right, not what's easy.
峰瑞资本·IPOs, Top 50 Best Returns, New Breakthroughs in Rocket Technology... 23 Milestones and 11 Reflections | FreeS Fund Blackboard · July
Do what's right, not what's easy.
峰瑞资本·FreeS Fund Report 16: The Truth About Early-Stage Healthcare Investing and China Speed | Frees Fund
Is early-stage healthcare investment really as "high-cost, high-risk, slow-return" as they say?
峰瑞资本·FreeS Fund Lands on 36Kr's "Top 10 Dark Horse Funds in China," Hard Tech Bets Earn LP Recognition
Do what's right, not what's easy.
峰瑞资本·Our Three Years: Experimenting, Exploring, and Pushing Forward
Still believing in the mission, still hoping to create value.
峰瑞资本·FreeS Fund Wins Three Awards at ChinaVenture's 2018 Annual Rankings
Do what is right, not what is easy.
峰瑞资本·FreeS Fund Is Hiring Investors | Let's Do What's Right, Not What's Easy
"The Summit" is rising — we're waiting for you!
峰瑞资本·New Zealand team-building, fundraising, new launches... Go strive, go make mistakes, go fall, go triumph in 2019 | FreeS Fund Chalkboard · January
Do what's right, not what's easy.
峰瑞资本·The Birth of a Retail Unicorn, Winning the Championship, and Finding the "Nail"... 12 Advances and 3 Insights | FreeS Fund Blackboard · October
Continuing to Push on Consumer and Deep Tech
峰瑞资本·
![[Live Tomorrow] In Conversation with Bluepha | Synthetic Biology: From Groping in the Dark to Riding the Wave](/_next/image?url=https%3A%2F%2Fkkcktdhgzddmdjdjoenc.supabase.co%2Fstorage%2Fv1%2Fobject%2Fpublic%2Fmedia%2Fimages%2F45f83c6a-7c35-4040-ba2d-210c7948ac95%2Fd7061a92cbcc.jpg&w=384&q=75)
